Market Snapshot: Gram-Negative Antibiotics Progress As Urgency Grows
Executive Summary
Several antibiotics have moved into late-stage development to treat resistant gram-negative infections, with drug makers banking that the urgent need for new drugs will pave the way for swift regulatory reviews and premium pricing.
You may also be interested in...
Merck Sees Decades-Long Time Horizon For Novel Antibiotics
Merck is one of the few big pharmas still investing in early-stage antibiotic R&D and is focusing long term on novel antibody and small molecule approaches, but Infectious Disease Research VP Daria Hazuda predicts the timeline for delivering innovative breakthroughs will be long.
Teva’s Cubicin Authorized Generic Is First Rival To Merck’s Brand
Teva launched an authorized generic version of Merck’s blockbuster antibiotic, while Pfizer did not provide an update on the timeline of a generic launch for which a court decision paved the way.
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.